Ryota Ishiwata

644 total citations
6 papers, 560 citations indexed

About

Ryota Ishiwata is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Ryota Ishiwata has authored 6 papers receiving a total of 560 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 3 papers in Pulmonary and Respiratory Medicine and 1 paper in Molecular Biology. Recurrent topics in Ryota Ishiwata's work include Colorectal Cancer Treatments and Studies (3 papers), Gastric Cancer Management and Outcomes (3 papers) and Neutropenia and Cancer Infections (2 papers). Ryota Ishiwata is often cited by papers focused on Colorectal Cancer Treatments and Studies (3 papers), Gastric Cancer Management and Outcomes (3 papers) and Neutropenia and Cancer Infections (2 papers). Ryota Ishiwata collaborates with scholars based in Japan, France and United States. Ryota Ishiwata's co-authors include Satoshi Teramukai, Yoji Nagai, Shigemi Matsumoto, Takeharu Yamanaka, Masanori Fukushima, Masakazu Fukushima, Agnès Viale, David R. Shaffer, Margaret Leversha and Howard I. Scher and has published in prestigious journals such as Proceedings of the National Academy of Sciences, British Journal of Cancer and Cancer Chemotherapy and Pharmacology.

In The Last Decade

Ryota Ishiwata

6 papers receiving 549 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ryota Ishiwata Japan	6	436	178	146	104	62	6	560
Hongyu Gao China	9	315 0.7×	217 1.2×	125 0.9×	89 0.9×	84 1.4×	14	534
Xun Yang China	14	377 0.9×	178 1.0×	274 1.9×	99 1.0×	31 0.5×	47	574
Yuichiro Umemoto Japan	7	408 0.9×	131 0.7×	108 0.7×	122 1.2×	114 1.8×	7	594
Katrin Hefler‐Frischmuth Austria	11	204 0.5×	118 0.7×	71 0.5×	59 0.6×	56 0.9×	17	479
Gary B. Deutsch United States	15	356 0.8×	119 0.7×	232 1.6×	49 0.5×	70 1.1×	45	597
Renjian Jiang United States	16	406 0.9×	220 1.2×	209 1.4×	151 1.5×	23 0.4×	61	689
Akinari Miyazaki Japan	8	428 1.0×	278 1.6×	236 1.6×	74 0.7×	40 0.6×	22	575
Ping‐Tsung Chen Taiwan	14	201 0.5×	126 0.7×	120 0.8×	59 0.6×	66 1.1×	35	436
N. Santana Spain	5	303 0.7×	199 1.1×	153 1.0×	27 0.3×	28 0.5×	8	574
P. Foa Italy	13	244 0.6×	138 0.8×	149 1.0×	37 0.4×	37 0.6×	26	507

Countries citing papers authored by Ryota Ishiwata

Since Specialization

Citations

This map shows the geographic impact of Ryota Ishiwata's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryota Ishiwata with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryota Ishiwata more than expected).

Fields of papers citing papers by Ryota Ishiwata

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryota Ishiwata. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryota Ishiwata. The network helps show where Ryota Ishiwata may publish in the future.

Co-authorship network of co-authors of Ryota Ishiwata

This figure shows the co-authorship network connecting the top 25 collaborators of Ryota Ishiwata. A scholar is included among the top collaborators of Ryota Ishiwata based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryota Ishiwata. Ryota Ishiwata is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Ishida, Takanori, Takayoshi Kiba, Motohiro Takeda, et al.. (2008). Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes. Cancer Chemotherapy and Pharmacology. 64(2). 361–369. 28 indexed citations

2.

Yamanaka, Takeharu, Shigemi Matsumoto, Satoshi Teramukai, et al.. (2007). Analysis of risk factors for severe adverse effects of oral 5-fluorouracil S-1 in patients with advanced gastric cancer. Gastric Cancer. 10(2). 129–134. 16 indexed citations

3.

Yamanaka, Takeharu, Shigemi Matsumoto, Satoshi Teramukai, et al.. (2007). The Baseline Ratio of Neutrophils to Lymphocytes Is Associated with Patient Prognosis in Advanced Gastric Cancer. Oncology. 73(3-4). 215–220. 400 indexed citations

4.

Yamanaka, Takeharu, Shigemi Matsumoto, Satoshi Teramukai, et al.. (2007). Safety evaluation of oral fluoropyrimidine S-1 for short- and long-term delivery in advanced gastric cancer: analysis of 3,758 patients. Cancer Chemotherapy and Pharmacology. 61(2). 335–343. 19 indexed citations

5.

Yamanaka, Takeharu, Shigemi Matsumoto, Satoshi Teramukai, et al.. (2007). Predictive value of chemotherapy-induced neutropenia for the efficacy of oral fluoropyrimidine S-1 in advanced gastric carcinoma. British Journal of Cancer. 97(1). 37–42. 69 indexed citations

6.

Shaffer, David R., Agnès Viale, Ryota Ishiwata, et al.. (2004). Evidence for a p27 tumor suppressive function independent of its role regulating cell proliferation in the prostate. Proceedings of the National Academy of Sciences. 102(1). 210–215. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact